tbuckley/cabot-search huggingface dataset:
Unfavourable effects of medically indicated oral anticoagulants on survival in idiopathic pulmonary fibrosis: methodological concerns
Authors: Michael Kreuter, Marlies S. Wijsenbeek, Martina Vasakova, Paolo Spagnolo, Martin Kolb, Ulrich Costabel, Derek Weycker, Klaus-Uwe Kirchgaessler, Toby M. Maher
Journal: European Respiratory Journal (2016)

We read the correspondence of L. Kawano-Dourado and colleagues related to our article "Unfavourable effects of medically indicated oral anticoagulants on survival in idiopathic pulmonary fibrosis" with great interest [1]. There is compelling evidence of an association between disturbances in the coagulation system and idiopathic pulmonary fibrosis (IPF); however, results from the ACE-IPF (anticoagulant effectiveness in idiopathic pulmonary fibrosis) randomised controlled trial of the vitamin K antagonist warfarin demonstrated deleterious effects of anticoagulation in IPF [2]. Based on these data, the recent update of the international guideline on IPF gave a strong recommendation against the use of anticoagulants [3]. Yet, the potential risks of medically indicated anticoagulation on mortality and other clinical outcomes in IPF remain unexplored. This is an important clinical question as almost one in every five patients with IPF receives anticoagulants for different indications [4]. In this regard, our post hoc analysis, which describes that patients in the placebo groups treated with anticoagulants in the CAPACITY and ASCEND trials had a higher rate of all-cause and IPF-related mortality compared with non-users, adds further insights in to the potential hazard of anticoagulant use in IPF [1]. We agree with Kawano-Dourado and colleagues that these data should be interpreted in light of the inherent limitations of a post hoc analysis based on a small number of events. However, these data represent, to our knowledge, the largest cohort of IPF subjects in whom this question has been addressed. Furthermore, our data are in line with two retrospective studies in IPF populations that also report a significantly higher risk of mortality in association with the use of anticoagulants for medical indications [5, 6] and this important clinical problem has recently also been highlighted by others [7]. Comorbidities requiring anticoagulants may not explain unfavourable effects of these drugs on survival in IPF <http://ow.ly/tmgm302VEXz>
Improving Appropriate Neurologic Prognostication after Cardiac Arrest. A Stepped Wedge Cluster Randomized Controlled Trial
Authors: Damon C. Scales, Eyal Golan, Ruxandra Pinto, Steven C. Brooks, Martin Chapman, Craig M. Dale, Draga Jichici, Gordon D. Rubenfeld, Laurie J. Morrison
Journal: American Journal of Respiratory and Critical Care Medicine (2016)

Rationale: Predictions about neurologic prognosis that are based on early clinical findings after out-of-hospital cardiac arrest (OHCA) are often inaccurate and may lead to premature decisions to withdraw life-sustaining treatments (LST) in patients who might otherwise survive with good neurologic outcomes.Objectives: To improve adherence to recommendations for appropriate neurologic prognostication after OHCA and reduce deaths from premature decisions to withdraw LST.Methods: This was a pragmatic stepped wedge cluster randomized controlled trial evaluating a multifaceted quality intervention (education, pathways, local champions, audit-feedback). The primary outcome was appropriate neurologic prognostication, defined as (1a) no early withdrawal of LST (WLST) (within 72 h) based on estimates of poor neurologic prognosis and (1b) no WLST between 72 hours and 7 days in absence of clinical predictors of poor neurologic prognosis or (2) surviving beyond 7 days. Secondary outcomes were deaths from early WLST and survival with good neurologic outcome.Measurements and Main Results: Between June 1, 2011, and June 30, 2014, a total of 905 patients with OHCA were enrolled from ICUs of 18 Ontario hospitals. Rates of appropriate neurologic prognostication increased after the intervention (68% vs. 74% patients; odds ratio [OR], 1.79; 95% confidence interval [CI], 1.01–3.19; P = 0.05). However, rates of survival to hospital discharge (46% vs. 50%; OR, 1.71; 95% CI, 0.97–3.01; P = 0.06) and survival with good neurologic outcome remained similar (38% vs. 43%; OR, 1.43; 95% CI, 0.84–2.86; P = 0.19).Conclusions: A multicenter quality intervention improved rates of appropriate neurologic prognostication after OHCA but did not increase survival with good neurologic outcome.Clinical trial registered with www.clinicaltrials.gov (NCT 01472458).
TCT-85 Prevalence of tricuspid regurgitation and its impact on mid-term outcomes: insights from a tertiary referral center
Authors: Claudio Montalto, Antonio Mangieri, Richard Jabbour, Pierpasqaule Leone, Matteo Pagnesi, Damiano Regazzoli, Eustachio Agricola, Paolo Camici, Antonio Colombo, Azeem Latib
Journal: Journal of the American College of Cardiology (2016)
EFFECT OF 4 WEEKS HIGH-INTENSITY INTERMITTENT TAEKWONDO TRAINING ON BODY COMPOSITION AND PHYSICAL FITNESS IN ZULU DESCENT, SOUTH AFRICAN TAEKWONDO ATHLETES
Authors: ML Mathunjwa, SC Mugandani, AP Kappo, S Ivanov, T Djarova-Daniels
Journal: British Journal of Sports Medicine (2016)

The aim of the present study was to determine the effect of 4 weeks high intensity intermittent Taekwondo (TKD) training program on body composition, physical fitness and performance of South African TKD athletes of Zulu ancestry. Thirty four (n=34) active TKD athletes aged 20–26 years volunteered for this study. The athletes were divided into control and experimental groups. The control participants (10 males and 7 females) were holders of green and lower belts with provincial exposure. The experimental group (10 males and 7 females) had blue or senior belts who qualified to represent the provincial club and to compete in International championships. Both groups were subjected to a 4 week of TKD and strength training. The experimental group performing high intensity intermittent (85–95%VO2max) training and control group performing interval TKD training of lower intensity (70–75% VO2max). All subject were pre and post-tested on body composition [body mass, BMI, body fat percentage (%BF), sum of 6 skinfolds (SS)], flexibility (sit &amp; reach), leg power (standing broad jump), muscle strength and endurance (sit-ups and push-ups), and agility (T-test) and VO 2max (20 m bleep test). Resting heart rate (RHR), systolic blood pressure (SBP) and diastolic blood pressure (DBP) were measured. Data was analyzed using paired t -test for independent samples and Z-score individual radar plots statistics. After 4 weeks of training, athletes in the experimental group showed a reduction in body weight (p&lt;0.05), BMI (p&lt;0.001), SBP (p&lt;0.05), RHR (p&lt;0.05), SS (p&lt;0.05), and fat % (p&lt;0.001) and improvement (p&lt;0.001) in flexibility, muscle strength, power, agility and VO 2max . In male controls, fat % was decreased (p&lt;0.05), flexibility and VO 2max were increased (p&lt;0.05). In female controls, only flexibility was improved (p&lt;0.05). The findings of this study support the effectiveness of 4 weeks high intensity intermittent training in Taekwondo athletes of Zulu ancestry improves body composition, cardiorespiratory response and physical performance that could contribute to health and enhanced combat skills.
FORMACIÓN EN DISECCIÓN ENDOSCÓPICA SUBMUCOSA COLORRECTAL (DES-CR) SIN EXPERIENCIA PREVIA GÁSTRICA. METODOLOGÍA Y VALORACIÓN DE RESULTADOS CLÍNICOS A 3 AÑOS
Authors: F Ramos-Zabala, J Rodríguez-Pascual, L Moreno Almazán, A Domínguez Pino, JM Cárdenas Rebollo, M García-Mayor, A Alzina Pérez, J Vásquez Guerrero, I Kovtun, FJ Pérez Rodríguez
Journal: Endoscopy (2016)

Introducción: La DES-CR es difícil de implantar debido a la larga curva de aprendizaje y a los riesgos de la técnica.
MINI01.13: Prediction of Lung Toxicity in the Definitive Radiotherapy of Non–Small Cell Lung Cancer using Clinical, Dosimetric and Biologic Factors
Authors: Peter G. Hawkins, Philip S. Boonstra, Randall K. Ten Haken, Martha M. Matuszak, Feng-Ming (Spring) Kong, Theodore S. Lawrence, Matthew J. Schipper, Shruti Jolly
Journal: Journal of Thoracic Oncology (2016)
TCT-445 Does the Risk of Bleeding Impacts Selection of Stent Type during Percutaneous Coronary Intervention?
Authors: Sang Yeub Lee, Rebecca Torguson, Hector M. Garcia-Garcia, Gilbert Tang, Toby Rogers, Sarkis Kiramijyan, Edward Koifman, Smita I. Negi, Jiaxiang Gai, Lowell Satler, Augusto Pichard, Ron Waksman
Journal: Journal of the American College of Cardiology (2016)
PS01.46: Robotic Thymectomy: Early Stage Thymoma and Non-Tumor Benign Lesions has Comparable Perioperative Outcomes
Authors: Mohamed Kamel, Mohamed Rahouma, Galal Ghaly, Abu Nasar, Brendon M. Stiles, Nasser K. Altorki, Jeffrey L. Port
Journal: Journal of Thoracic Oncology (2016)
Chronic Graft-Versus-Host Disease and Its Association with Treatment-Related Mortality, Relapse, Leukemia-Free and Overall Survival After Umbilical Cord Blood Transplantation (UCBT) In Children and Adolescents with Acute Leukemia
Authors: Mary Eapen, Tao Wang, Joanne Kurtzberg, Stephanie J. Lee, Reggie Duerst, Mukta Arora, Carmem Bonfim, Michel Duval, Gretchen Eames, Karin Tiedemann, Daniel J. Weisdorf, John E. Wagner
Journal: Blood (2010)
TCT-330 Risk phenotype and clinical outcomes of patients with stable coronary artery disease treated with PCI stratified by baseline LDL cholesterol
Authors: Michela Faggioni, Jaya Chandrasekhar, Usman Baber, Annapoorna Kini, Gennaro Giustino, Jason Kovacic, Serdar Farhan, Samin Sharma, Melissa Aquino, Prakash Krishnan, Pedro Moreno, George Dangas, Roxana Mehran
Journal: Journal of the American College of Cardiology (2016)
TCT-183 Deferred versus Conventional stent implantation in patients with acute ST-segment elevation myocardial infarction: an updated meta-analysis of 10 Studies
Authors: Joo Myung Lee, Tae-Min Rhee, Doyeon Hwang, Jonghanne Park, Haseong Chang, Ahn Chul, Seung-Hyuck Choi, Hyeon-Cheol Gwon, Joo-Yong Hahn
Journal: Journal of the American College of Cardiology (2016)
Cost‐effectiveness of augmenting current perinatal hepatitis B prevention program with maternal antiviral therapy
Authors: Gang Qin, Xun Zhuang
Journal: Hepatology (2016)

Supported, in part, by grants from Jiangsu Provincial Department of Science and Technology (no. BE2015655), China, and the National Natural Science Foundation of China (nos. 81370520 and 81373060). Potential conflict of interest: Nothing to report. TO THE EDITOR: We read with interest the well‐designed study by Fan et al.1 on cost‐effectiveness of the current perinatal hepatitis B (HepB) screening and immunization program versus augmenting this strategy with maternal antiviral therapy, with a Markov decision tree model involving perinatal hepatitis B virus (HBV) infection risks, long‐term health, and economic consequences. However, several aspects need clarification in this article. First, Fan et al. perform a thorough cost‐effectiveness analysis (CEA) on the lifelong costs and outcomes of three strategies for preventing perinatal HBV infection. A 78‐year cycle with a 1‐year interval is specified for the Markov model. Given that most infants and children with perinatal HBV infection maintain immune tolerance, the researchers start the Markov process at age 20 years. Considering the hypothetical 2010 birth cohort of 4 million infants and approximately 190 million quality‐adjusted life‐years (QALYs) for each strategy, there is an obvious discrepancy between the average 47.5 QALYs and the 78 years of life expectancy, probably attributed to exemption of the first 20 years' QALYs for the entire cohort. We suggest that these common QALYs should be included in the total rewards, while the final incremental cost‐effectiveness ratio (ICER) results remain the same. Second, the researchers summarize the parameter values and their ranges for the decision tree and Markov model in Table 1. Two baseline parameters, that is, cost for hepatitis B surface antigen screening test and HepB vaccination, are lacking. Actually, these costs contributed substantially to the total cost and should be listed in the article, as in other reports.2 Third, using one‐way sensitivity analyses, the researchers demonstrate that the antiviral prophylaxis remains cost‐effective over wide ranges of time‐varying and district‐specific factors. However, the results in Table 4 might be misleading because the ranges of output ICERs are not consistent with the interpretation within the text. For example, bigger reduction in perinatal HBV transmission (20%‐80%) from maternal antiviral therapy makes antiviral prophylaxis a more cost‐effective program (ICER $97,749/QALY—cost saving, rather than cost saving—$97,749/QALY), compared with the current strategy. Similarly, the ranges of $2,886‐$15,552/QALY, $3,961‐$11,131/QALY, cost saving—$269,796/QALY, $4,635‐$8,446/QALY, cost saving—$21,549/QALY and $6,876‐$8,926/QALY should be reversed or presented in a Tornado diagram as in other reports.3 Last, in CEA, the strategy of choice is usually determined by comparing the ICER to what decision makers are willing to pay (WTP) for an additional QALY.4 The discussion of WTP is lacking in the article.
Gemcitabine Mechanism of Action Confounds Early Assessment of Treatment Response by 3′-Deoxy-3′-[18F]Fluorothymidine in Preclinical Models of Lung Cancer
Authors: Sonja Schelhaas, Annelena Held, Lydia Wachsmuth, Sven Hermann, Davina J. Honess, Kathrin Heinzmann, Donna-Michelle Smith, John R. Griffiths, Cornelius Faber, Andreas H. Jacobs
Journal: Cancer Research (2016)

3'-Deoxy-3'-[
Clinical Significance of Sensitive Flow-MRD Monitoring in Elderly Multiple Myeloma Patients on the Pethema/GEM2010MAS65 Trial
Authors: Bruno Paiva, Maria Angeles Montalbán, Noemi Puig, Lourdes Cordon, Joaquin Martinez-Lopez, Enrique M Ocio, Miguel Hernandez, Ana Isabel Teruel, Mercedes Gironella, Maria Asunción Echeveste, Laura Rosiñol, Rafael Martinez, Albert Oriol, Jesus Martin, Cristina Encinas, Norma Carmen Gutierrez, María-Belén Vidriales, Joan Blade, Juan José Lahuerta, Maria-Victoria Mateos, Jesus F. San Miguel
Journal: Blood (2014)
Protective neutralizing influenza antibody response in the absence of T follicular helper cells
Authors: Kosuke Miyauchi, Akiko Sugimoto-Ishige, Yasuyo Harada, Yu Adachi, Yoshiko Usami, Tomohiro Kaji, Kentaro Inoue, Hideki Hasegawa, Takashi Watanabe, Atsushi Hijikata, Satoshi Fukuyama, Tadashi Maemura, Mariko Okada-Hatakeyama, Osamu Ohara, Yoshihiro Kawaoka, Yoshimasa Takahashi, Toshitada Takemori, Masato Kubo
Journal: Nature Immunology (2016)
TCT-793 Results of a Japanese IDE Trial Using Stent-Grafts for Treatment of SFA Disease confirm the importance of optimal sizing
Authors: Takao Ohki, Kimihiko Kichikawa, Hiroyoshi Yokoi, Masaaki Uematsu, Terutoshi Yamaoka, Takeshi Baba, Reo Takizawa
Journal: Journal of the American College of Cardiology (2016)
TCT-233 Contemporary Use of Laser during Percutaneous Coronary Intervention: Initial Results from the Laser Veterans Affairs (LAVA) Registry
Authors: Judit Karacsonyi, Jose Roberto Martinez-Parachini, Aya Alame, Barbara Anna Danek, Aris Karatasakis, Phuong-Khanh Nguyen-Trong, Rahel Iwentu, Erica Resendes, Pratik Kalsaria, Michele Roesle, Imre Ungi, Subhash Banerjee, Emmanouil Brilakis, Bavana Rangan
Journal: Journal of the American College of Cardiology (2016)
TCT-263 Impact of Diabetes on Clinical Outcomes in Patients Undergoing Unprotected Left Main Percutaneous Coronary Intervention with Drug-Eluting Stents
Authors: Bo Xu, Jonathan Murphy, Yuejin Yang, Shubin Qiao, Changdong Guan, Runlin Gao, Ajay Kirtane
Journal: Journal of the American College of Cardiology (2016)
Nonmyeloablative HLA-Haploidentical (NMA Haplo) BMT with High-Dose Posttransplantation Cyclophosphamide (PTCy) Is Associated with Similar Outcomes to Matched BMT When Stratified By Disease Risk Index (DRI)
Authors: Shannon R. McCurdy, Jennifer A. Kanakry, Margaret M. Showel, Hua-Ling Tsai, Javier Bolaños-Meade, Christopher G. Kanakry, Douglas E. Gladstone, Leo Luznik, Carol Ann Huff, Lode J. Swinnen, Richard F. Ambinder, Richard J. Jones, Ephraim J. Fuchs, Yvette L. Kasamon
Journal: Blood (2014)
TCT-675 Futility in Transcatheter Aortic Valve Implantation: result from the Italian Multicenter OBSERVANT Study
Authors: Stefano Salizzoni, Paola D'Errigo, Crisitna Barbero, Luigina Ferrigno, Stefano Rosato, Marco Barbanti, Corrado Tamburino, Mauro Rinaldi, Fulvia Seccareccia
Journal: Journal of the American College of Cardiology (2016)
Can We Improve Mortality Estimation in Women After Treadmill Testing by Using Sex-Specific Scores?
Authors: Ashok Krishnaswami, Jeff W. Christle, Victor Froelicher
Journal: JAMA Cardiology (2016)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA Cardiology HomeNew OnlineCurrent IssueFor Authors Podcast Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA Cardiology journal
TCT-329 Impaired HDL uptake capacity which measure HDL functionality may associate with target lesion revascularization through provoking neoatherosclerosis formation after stent implantation
Authors: Yuichiro Nagano, Hiromasa Otake, Amane Harada, Katsuhiro Murakami, Maria Kiriyama, Yasuhiro Irino, Takayoshi Toba, Hachidai Takahashi, Daisuke Terashita, Koji Kuroda, Kenzo Uzu, Natsuko Tahara, Yuto Shinkura, Yoshinori Nagasawa, Yoshiro Tsukiyama, Kenichi Yanaka, Hiroyuki Yamamoto, Toshiro Shinke, Tatsuro Ishida, Ryuji Toh, Ken-ichi Hirata
Journal: Journal of the American College of Cardiology (2016)
TCT-364 Radial vs Femoral Access for Coronary Angiography and Intervention in the Elderly (&gt;75) - a Meta-analysis and Subgroup Analysis (All studies vs Octagenarian studies, N. America studies vs Rest of the World studies)
Authors: Claire Lynch, Kiran Sarathy, Jennifer Yu, Nigel Jepson, Sze-Yuan Ooi, Kevin Liou
Journal: Journal of the American College of Cardiology (2016)
TCT-760 Predictors of Elevated Tumor Marker Carbohydrate Antigen 125 in Patients Undergoing Transcatheter Aortic Valve Implantation
Authors: Tobias Rheude, Costanza Pellegrini, Teresa Trenkwalder, Jonathan Michel, Markus Kasel, Heribert Schunkert, Adnan Kastrati, Christian Hengstenberg, Oliver Husser
Journal: Journal of the American College of Cardiology (2016)
エキシマレーザー冠血管形成術(ELCA)が有効であった労作性狭心症の2例
Authors: 浜中一郎, 上田欽造, 富士榮博昭, 皿澤克彦, 稲井理仁, 北川元昭, 高橋伸基, 山崎武俊, 赤城格, 田邉昌人, 浜典男, 平岡勇二
Journal: Circulation (2006)
TCT-639 The Impact of Mitral Regurgitation Severity on Efficacy of Percutaneous Mitral Valve Annuloplasty in Functional Mitral Regurgitation
Authors: Horst Sievert, Michael Haude, Hubertus Degen, Janusz Lipiecki, Steven Goldberg, Tomasz Siminiak
Journal: Journal of the American College of Cardiology (2016)
A multicenter randomized phase II study of full-dose gemcitabine and concurrent radiotherapy comparing gemcitabine alone for the unresectable locally advanced pancreatic adenocarcinoma
Authors: T. Ioka, R. Takakura, A. Nakaizumi, S. Tanaka, H. Iishi, S. Nakamura, K. Nishiyama, H. Oohigashi, O. Ishikawa, A. Watanabe, S. Mukai
Journal: Journal of Clinical Oncology (2009)

e15512 Background: Some of locally advanced pancreatic cancers (LAPC) are considered to include a potential micro metastasis. We think that full-dose of gemcitabine (GEM) improve the outcome of LAPC. We report the efficacy of full-dose GEM and concurrent radiotherapy, comparing GEM alone for unresectable LAPC. Methods: Patients with histologically or cytologically proven pancreatic adenocarcinoma were eligible for this study. We decide that LAPA which involved a major artery with CT imaging was unresectable. Patients were randomized into a concurrent chemoradiotherapy (CRT) group and a chemotherapy alone (CTX) group. GEM was given intravenously at a dose of 1,000 mg/msq over 30 min on days 1, 8 and 15 of each 28-day cycle and repeated until disease progression in both groups. Patients randomized into CRT group received a limited field irradiation with a total dose of 50 Gy in 25 sessions during first two cycles. The two groups were compared for mean survival, progression free survival and safety. Results: From September 2002 to April 2005, 80 patients were randomized at two institutions into the two arms of the trial (40 patients to CRT group and 40 patients to CTX group). The CRT group had better results than the CTX group as measured by mean survival time (391 vs 372 days, P&lt; 0.02) and progression free survival (237 vs 128 days, P&lt; 0.01). There were no differences in the safety between both groups. Conclusions: The concurrent chemoradiotherapy with full-dose GEM is effective and feasible in patients of LAPC compared with full-dose GEM alone. No significant financial relationships to disclose.
Wide Variation in Reported Rates of Stroke Across Cohorts of Patients With Atrial Fibrillation
Authors: Gene R. Quinn, Olivia N. Severdija, Yuchiao Chang, Daniel E. Singer
Journal: Circulation (2016)

Oral anticoagulants decrease ischemic stroke rates in patients with atrial fibrillation (AF) but increase the risk of bleeding. For the average patient with AF, the threshold of annual ischemic stroke rate where the benefit of anticoagulation outweighs the bleeding risk (net clinical benefit) has been shown to be ≈1% to 2%. Guideline recommendations for oral anticoagulants in AF are based on the CHA2DS2-VASc stroke risk point scores, assuming that those scores translate to fixed stroke rates. However, the relationship between stroke point scores and annual stroke rates may vary substantially across populations. We sought to comprehensively assess the reported rates of stroke in patients with AF and the relationship of stroke rates to stroke risk point scores.A systematic review of cohort studies and randomized controlled trials enrolled patients with nonvalvular AF not treated with oral anticoagulants.Of the 3552 studies screened, we identified 34 studies eligible for analysis. Overall stroke rates in cohort studies were highly heterogeneous (Q=5706.54, P<0.001; I2 = 99.6%) and ranged from 0.45% to 9.28% per year, despite being of similar objective study quality. The mean North American stroke rate was less than one-third that of the mean European stroke rate (P<0.0001). However, a random effects regression indicated that between-study variability was not significantly accounted for by cohort region, prospective versus retrospective design, calendar year of study, or outcome event cluster. At a CHA2DS2-VASc score of 1, 76% of cohorts reported ischemic stroke rates <1% per year and only 18% of cohorts reported a stroke rate >2% per year. At a CHA2DS2-VASc score of 2, 27% of cohorts reported stroke rates below 1% per year, 40% reported stroke rates between 1 and 2% per year, and 33% reported stroke rates >2% per year.Substantial variation exists across cohorts in overall stroke rates and rates corresponding to CHA2DS2-VASc point scores. These variations can affect the point score threshold for recommending oral anticoagulants in AF. The majority of cohorts did not observe stroke rates that would indicate a clear expected net clinical benefit for anticoagulating AF patients with CHA2DS2-VASc scores of 1 or 2.